A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer.

Abstract:

:The aim of this phase II study was to evaluate safety and efficacy of an oxaliplatin/vinorelbine/5-fluorouracil (FON) combination in anthracycline and taxane-pretreated metastatic breast cancer patients. The following treatment was given: on day 1 of a 21-day cycle, oxaliplatin 130 mg/m (2-h intravenous infusion); on days 1 and 5, vinorelbine [dose level (DL) 1: 17.5 mg/m; DL2: 22 mg/m]; on days 1-5, continuous infusion 5-fluorouracil (DL1: 600 mg/m/day; DL2: 750 mg/m/day). Forty-seven patients were treated (DL1: 43; DL2: 4). Median age was 54 years; 68% had liver metastases, 53% were taxane refractory/resistant and 38% were anthracycline refractory/resistant. Patients received a median of six treatment cycles. Of 46 eligible patients, 16 had partial response; the overall response rate was 34.8% (95% confidence interval 21.3-50.3%), 11 had stable disease lasting more than 4 months. Median follow-up was 13.0 months, median time to progression 5.7 months and estimated overall survival 18.8 months. DL2 was too toxic with three patients having grade 3-4 toxicity, including one death. At DL1, 26 patients (60%) experienced grade 3-4 neutropenia (six febrile neutropenia) and eight had grade 3 oxaliplatin-specific peripheral neuropathy after a median of 646.4 mg/m oxaliplatin (range 124-1619 mg/m). Oxaliplatin (130 mg/m, day 1)/vinorelbine (17.5 mg/m, days 1,5)/5-fluorouracil (600 mg/m/day, days 1-5) demonstrate encouraging activity and a manageable safety profile in anthracycline- and taxane-pretreated metastatic breast cancer patients.

journal_name

Anticancer Drugs

journal_title

Anti-cancer drugs

authors

Delozier T,Guastalla JP,Yovine A,Levy C,Chollet P,Mousseau M,Delva R,Coeffic D,Vannetzel JM,Zazzi ES,Brienza S,Cvitkovic E

doi

10.1097/01.cad.0000231475.77159.aa

subject

Has Abstract

pub_date

2006-10-01 00:00:00

pages

1067-73

issue

9

eissn

0959-4973

issn

1473-5741

pii

00001813-200610000-00009

journal_volume

17

pub_type

杂志文章
  • Doxorubicin induces apoptosis in Jurkat cells by mitochondria-dependent and mitochondria-independent mechanisms under normoxic and hypoxic conditions.

    abstract::In this study, we investigated the molecular mechanism of doxorubicin (dxr)-induced cytotoxicity on Jurkat cells - a model cell of human acute lymphoblastic leukemia - under normoxic (20% O2) and hypoxic (5% O2) conditions. Using in-cell western analysis, immunofluorescence, flow cytometry analysis, and biochemical in...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000223

    authors: Mendivil-Perez M,Velez-Pardo C,Jimenez-Del-Rio M

    更新日期:2015-07-01 00:00:00

  • Decreased topotecan platelet toxicity with successive topotecan treatment cycles in advanced ovarian cancer patients.

    abstract::The dose-limiting toxicities of the DNA topoisomerase I inhibitor topotecan are hematological. We prospectively analyzed the platelet toxicity pattern in patients receiving topotecan to optimize the clinical management of topotecan hematotoxicity. Twenty-one advanced ovarian cancer patients, all pretreated with cispla...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章

    doi:10.1097/00001813-199903000-00002

    authors: Goldwasser F,Buthaud X,Gross M,Bleuzen P,Cvitkovic E,Voinea A,Jasmin C,Romain D,Misset JL

    更新日期:1999-03-01 00:00:00

  • Isoquercitrin isolated from Hyptis fasciculata reduces glioblastoma cell proliferation and changes beta-catenin cellular localization.

    abstract::Isoquercitrin isolated from the aerial parts of Hyptis fasciculata was evaluated according to its capacity to interfere with glioblastoma (Gbm) cell growth. Gbm cells were incubated with isoquercitrin, quercetin, or rutin at concentrations of 25, 50, and 100 mumol/l for 24, 48, and 72 h. Quercetin and rutin affected G...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e32832d1149

    authors: Amado NG,Cerqueira DM,Menezes FS,da Silva JF,Neto VM,Abreu JG

    更新日期:2009-08-01 00:00:00

  • Extravasation accidents with liposomal/liposomal pegylated anthracyclines treated with dexrazoxane: an overview and outcomes.

    abstract::The extravasation of chemotherapeutic agents is a challenge for oncologic care teams. The management of nonliposomal (conventional) anthracyclines is well established in clinical practice guidelines, including general measures and specific antidotes, such as dexrazoxane. However, there is little scientific evidence on...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/CAD.0000000000000672

    authors: Caballero Romero Á,Delgado Ureña MT,Salmerón García A,Megías Fernández MT,Librada Porriño-Bustamante M,Cabeza Barrera J

    更新日期:2018-10-01 00:00:00

  • Methotrexate concentrations in cerebrospinal fluid and serum, and the risk of central nervous system relapse in children with acute lymphoblastic leukaemia.

    abstract::The aim of the study was to characterize the relationship between the pharmacokinetics of methotrexate in serum and concentrations in the cerebrospinal fluid, and to analyse the association to risk of a central nervous system relapse in children with acute lymphoblastic leukaemia. In this retrospective study, 353 chil...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e3281430bd1

    authors: Jönsson P,Höglund P,Wiebe T,Schrøder H,Seidel H,Skärby T

    更新日期:2007-09-01 00:00:00

  • Docetaxel: an interesting new drug for the treatment of head and neck cancers and soft tissue sarcomas.

    abstract::Results are summarized for two phase II studies of docetaxel as first-line therapy for advanced squamous cell carcinoma of the head and neck (SCCHN) and one study of docetaxel as second-line therapy for advanced soft tissue sarcomas. In all three studies, docetaxel was administered at a dose of 100 mg/m2 by intravenou...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1097/00001813-199507004-00004

    authors: Verweij J

    更新日期:1995-07-01 00:00:00

  • Local injection of M-CH combined with i.p. hyperthermic hypo-osmolar infusion is an effective therapy in advanced gastric cancer.

    abstract::Treatment failure of surgically treated gastric cancer is attributed to the spread of gastric cancer cells into the abdominal cavity and lymphatic or hematogenic canals. In the present study, local injection of mitomycin C bound to activated carbon (M-CH) combined with i.p. hyperthermic hypo-osmolar infusion (IPHHOI) ...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00001813-200204000-00013

    authors: Huang Y,Hagiwara A,Wang W,Su G,Qi X,Ma D,Fan Y

    更新日期:2002-04-01 00:00:00

  • The inhibition of growth and down-regulation of gonadotropin releasing hormone (GnRH) receptor in alphaT3-1 cells by GnRH agonist.

    abstract::Gonadotropin releasing hormone (GnRH) and its analogs inhibit the growth of hormone-dependent tumors in vivo and in vitro. The inhibition of growth and proliferation of tumor cells in vitro by GnRH and its analogs indicates that the tumor suppressing effect of the hormone is only partially due to suppression of pituit...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199704000-00009

    authors: Kakar SS,Nath S,Bunn J,Jennes L

    更新日期:1997-04-01 00:00:00

  • Induction chemotherapy in head and neck cancer: a new paradigm.

    abstract::Five hundred and fifty thousand new head and neck cancer cases are diagnosed each year worldwide. They are mostly locally advanced squamous cell carcinoma with a poor prognosis in terms of locoregional and distant failure. A major challenge for patients with locally advanced squamous cell carcinoma is to achieve a hig...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/CAD.0b013e3283425871

    authors: Pointreau Y,Atean I,Fayette J,Calais G,Lefebvre JL

    更新日期:2011-08-01 00:00:00

  • Imatinib mesylate (STI571; Glivec)--a new approach in the treatment of biliary tract cancer?

    abstract::Non-resectable biliary tract cancer is associated with poor prognosis due to widespread resistance to chemotherapeutic agents and radiotherapy. It is therefore essential to explore new therapeutic approaches like the inhibition of tyrosine kinases. The aim of this study was to determine the expression of c-kit and pla...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200310000-00011

    authors: Wiedmann M,Kreth F,Feisthammel J,Deininger M,Mössner J,Caca K

    更新日期:2003-10-01 00:00:00

  • [Current treatment of bladder cancer: from epidemiology to surgical treatment].

    abstract::Urothelial carcinoma of the bladder accounts for over 95% of bladder tumours in France. The incidence of this disease is increasing in industrialised countries. Several types of bladder cancer can be distinguished: (1) superficial tumours which have a risk of recurrence and progression, although conservative treatment...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:

    authors: Rischmann P

    更新日期:2000-10-01 00:00:00

  • Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity.

    abstract::Chemotherapy for breast cancer is given on the basis of empirical information from clinical trials, an approach which falls to take into account the known heterogeneity of chemosensitivity between patients. Previous attempts to determine chemosensitivity ex vivo have been disappointing, but in this study results from ...

    journal_title:Anti-cancer drugs

    pub_type: 临床试验,杂志文章

    doi:10.1097/00001813-199608000-00002

    authors: Cree IA,Kurbacher CM,Untch M,Sutherland LA,Hunter EM,Subedi AM,James EA,Dewar JA,Preece PE,Andreotti PE,Bruckner HW

    更新日期:1996-08-01 00:00:00

  • Potential antineoplastic activity of keto-C-glycosides--a new family of cytostatic agents.

    abstract::We have examined the biological activity of keto-C-glycosides (KCGs), a new family of drugs displaying antiproliferative and cytotoxic properties on tumor cells. KCG1, the most powerful drug tested on epithelial derived neoplastic cells, was 25-125 times more cytostatic on epithelial cells than on lymphoma. By contras...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199208000-00006

    authors: Bennani-Baïti MI,Lafarge-Frayssinet C,Herscovici J,Monserret R,Antonakis K,Frayssinet C,Uriel J

    更新日期:1992-08-01 00:00:00

  • S-allylcysteine induces cytotoxic effects in two human lung cancer cell lines via induction of oxidative damage, downregulation of Nrf2 and NF-κB, and apoptosis.

    abstract::In this study, we investigated the putative cytotoxic effect elicited by the garlic-derived compound S-allylcysteine (SAC) in two human cancer cell lines (HCC827 and NCI-H1975) in order to develop an experimental approach to the therapeutic potential of this molecule for lung cancer. Cells were incubated for 24, 48 an...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000001015

    authors: Orozco-Morales M,Hernández-Pedro NY,Barrios-Bernal P,Arrieta O,Ruiz-Godoy LM,Aschner M,Santamaría A,Colín-González AL

    更新日期:2021-02-01 00:00:00

  • Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial.

    abstract::The objective of this study was to evaluate intravesical gemcitabine in high-risk nonmuscle-invasive bladder cancer (NMIBC) refractory to bacillus Calmette-Guérin (BCG). This was a prospective multicentre single-arm trial. Eligible patients were those with high-risk NMIBC refractory to BCG therapy, for which radical c...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,多中心研究

    doi:10.1097/CAD.0b013e3283324d83

    authors: Perdonà S,Di Lorenzo G,Cantiello F,Damiano R,De Sio M,Masala D,Bruni G,Gallo L,Federico P,Quattrone C,Pizzuti M,Autorino R

    更新日期:2010-01-01 00:00:00

  • Generation of DNA damage by anti-neoplastic agents.

    abstract::DNA has been one of the major targets of cancer chemotherapy. A variety of anti-neoplastic agents can cause different types of DNA lesions, including base alterations, single- or double-strand DNA breaks, DNA-DNA cross-links and DNA-protein cross-links. The exact processes by which these DNA lesions lead to cell death...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/00001813-199112000-00003

    authors: Kubota M

    更新日期:1991-12-01 00:00:00

  • Compatibility and stability of Imexon in infusion devices and its in vitro biocompatibility.

    abstract::Imexon is an investigational anti-cancer agent, pharmaceutically formulated as a lyophilized solid for i.v. infusion requiring reconstitution and subsequent dilution in infusion fluid before infusion. Imexon contains a highly reactive aziridine ring in its structure, which limits its stability in aqueous solutions. In...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/01.cad.0000172833.70444.ba

    authors: den Brok MW,Nuijen B,Challa EE,Lutz C,Opitz HG,Beijnen JH

    更新日期:2005-08-01 00:00:00

  • Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell line.

    abstract::The clinical development of combinations of cisplatin or carboplatin with DNA topoisomerase I (Topo I) inhibitors is based on their overlapping spectrum of antitumor activity and their in vitro synergy, but is limited by significant hematotoxicity. We studied the cellular interactions between oxaliplatin and topotecan...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199902000-00008

    authors: Goldwasser F,Bozec L,Zeghari-Squalli N,Misset JL

    更新日期:1999-02-01 00:00:00

  • All-trans retinoic acid suppresses topoisomerase IIα through the proteasomal pathway.

    abstract::Topoisomerase IIα is a nuclear enzyme that alters DNA topology. It is a well-known anticancer target and related to cell differentiation status. All-trans retinoic acid (ATRA), an important active metabolite of vitamin A, is a promising anticancer agent in numerous malignancies. However, there are little data on the e...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000241

    authors: Li X,Li Y,Shen X,Fu S,Han S,Feng Q

    更新日期:2015-08-01 00:00:00

  • 7-Keto hybrid steroidal esters of nitrogen mustard: cytogenetic and antineoplastic effects.

    abstract::Four newly synthesized antitumor steroidal compounds were compared, on a molar basis, regarding their ability to induce sister chromatid exchanges (SCEs) and cell division delays. The concept of designing and developing these compounds (1-4) is to enhance the anticancer activity of esteric steroidal derivatives of nit...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200207000-00011

    authors: Karayianni V,Papageorgiou A,Mioglou E,Iakovidou Z,Mourelatos D,Fousteris M,Koutsourea A,Arsenou E,Nikolaropoulos S

    更新日期:2002-07-01 00:00:00

  • The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer.

    abstract::Low doses of drugs delivered at close, regular intervals are increasingly being used to manage patients with different neoplasms. Despite the good tolerability, treatment-related adverse events still occur following metronomic protocols. The aim of this study was to retrospectively investigate whether polymorphisms of...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0000000000000429

    authors: Romiti A,Roberto M,D'Antonio C,Onesti CE,Barucca V,Milano A,Gentile G,Lionetto L,Medda E,Mazzuca F,Botticelli A,Falcone R,Simmaco M,Marchetti P

    更新日期:2016-11-01 00:00:00

  • Use of corticosteroids in neuro-oncology.

    abstract::Glucocorticosteroids (GC) play an important role in the treatment of neuro-oncologic patients. GC are used for the management of malignant brain tumors, either primary of secondary, neoplastic epidural spinal cord compression (NESC), as adjuvant chemotherapy of some central nervous system tumors and perioperatively in...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/00001813-199502000-00002

    authors: Koehler PJ

    更新日期:1995-02-01 00:00:00

  • Structure-activity studies on gossypol in tumor cell lines.

    abstract::Gossypol [(2,2'-binaphthalene)-8,8'-dicarboxaldehyde-1,1',6,6',7,7'-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl] 1a is a naturally occurring compound extracted from the cotton plant and has been extensively studied as an oral male contraceptive. Its favorable toxicity profile, and the more recent demonstration of anti-...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200003000-00009

    authors: Shelley MD,Hartley L,Groundwater PW,Fish RG

    更新日期:2000-03-01 00:00:00

  • Phthalimide analogs of CB 1954: synthesis and bioactivation.

    abstract::Four novel 4-substituted 5-nitrophthalimides (5-substituted-6-nitro-1,3-dihydro-isoindol-1,3-diones), 6, 7, 10 and 11, and the known 5 are prepared as analogs of the dinitrobenzamide prodrug CB 1954, 1, and considered as potential candidates for gene-directed enzyme prodrug therapy. All the phthalimides are poor subst...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-199909000-00011

    authors: Mehta LK,Hobbs S,Chen S,Knox RJ,Parrick J

    更新日期:1999-09-01 00:00:00

  • Activation of c-Jun N-terminal kinase is required for mevastatin-induced apoptosis of salivary adenoid cystic carcinoma cells.

    abstract::Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase, originally developed for lowering cholesterol. Statins also have pleiotropic effects, independent of cholesterol-lowering effects, including induction of apoptosis in various cell lines. However, the mechanism underlying statin-induced apoptosi...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:

    authors: Zhang S,Wang XL,Gan YH,Li SL

    更新日期:2010-08-01 00:00:00

  • Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer.

    abstract::The efficacy of chemotherapy for advanced gastric cancer with palliative intent compared with supportive care alone is now widely accepted. However, the best choice of chemotherapy regimen for patients with advanced gastric cancer is still a matter of controversy and requires further investigation. This study is perfo...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e3283273509

    authors: Cao W,Yang W,Lou G,Jiang J,Geng M,Xi W,Li H,Ma T,Jin Y

    更新日期:2009-04-01 00:00:00

  • Exploring the lack of cross-resistance between aromatase inhibitors: evidence for a difference?

    abstract::A lack of cross-resistance between the aromatase inhibitors (AIs) provides evidence to suggest that there are clinical differences between these agents. Available data from clinical trials indicate that patients exposed to nonsteroidal AIs may benefit from a steroidal compound of similar biochemical potency, and durab...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/01.cad.0000277875.81122.25

    authors: Lønning PE

    更新日期:2008-03-01 00:00:00

  • Are there benefits in routine clinical practice of continuing trastuzumab after progression for metastatic breast cancer patients?

    abstract::The efficacy of trastuzumab beyond metastatic disease progression (PD) is controversial. We retrospectively analyzed 213 patients with HER2-positive metastatic breast cancer treated with trastuzumab-based therapies between November 1998 and December 2010. Out of 213 patients, 134 (58%) had received trastuzumab consecu...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/CAD.0b013e32835679d3

    authors: Esposito A,Munzone E,Bagnardi V,Adamoli L,Sciandivasci A,Cullurà D,Goldhirsch A,Nolè F

    更新日期:2012-11-01 00:00:00

  • Differences in the apoptosis-inducing properties of Viscum album L. extracts.

    abstract::Viscum album L. (mistletoe) extracts are widely used in adjuvant cancer therapy. In contrast to purified components, such as mistletoe lectins and viscotoxins, whole plant extracts of mistletoe resulted in DNA stabilizations in cyclophosphamide-treated lymphocytes but also provided cytotoxicity in tumour cells and lym...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章,评审

    doi:10.1097/00001813-199704001-00003

    authors: Büssing A,Suzart K,Schweizer K

    更新日期:1997-04-01 00:00:00

  • No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel.

    abstract::We have investigated the pharmacokinetics of nevirapine and paclitaxel in a patient who used both drugs concomitantly, as there are strong theoretical indications for a potential pharmacokinetic drug-drug interaction. Plasma concentrations of nevirapine (dose: 200 mg twice daily orally) and paclitaxel (dose: 100 mg/m(...

    journal_title:Anti-cancer drugs

    pub_type: 杂志文章

    doi:10.1097/00001813-200507000-00006

    authors: Kappelhoff BS,Huitema AD,Mairuhu AT,Schellens JH,Beijnen JH

    更新日期:2005-07-01 00:00:00